News & Events
- Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates
- Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
- Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
- Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation
- Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights
- Seres Therapeutics to Present at the Cowen 2020 Health Care Conference
- Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020
- Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
- Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors
- Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's <em>Opdivo®</em> (Nivolumab)
- Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab)
- Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
- Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference
- Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders
- Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update